Use of an il12 receptor-beta 1 splice variant to diagnose active tuberculosis
AssigneeTrudeau Institute
InventorsRichard T. Robinson, Andrea M. Cooper
Life of this patent
Estimating the term…
Abstract
The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M. tuberculosis infection. In another embodiment, the present invention contemplates a method of monitoring a M. tuberculosis infection. In yet another embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection. In a further embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection.
Claims26
A method of identifying an active M. tuberculosis infection, comprising:
- a) providing a patient infected with M. tuberculosis,
- b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell,
- c) diagnosing the patient as having an active M. tuberculosis infection if the amount of IL12Rβ1 isoform 2 mRNA is greater than the amount of IL12Rβ1 isoform 1 mRNA,
- d) initiating a therapeutic treatment on said patient with an active M. tuberculosis infection.
(canceled)
A method of identifying an active M. tuberculosis infection, comprising:
- a) providing a patient suspected of being infected with M. tuberculosis,
- b) determining the amount of EL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell,
- c) diagnosing the patient as having an active M. tuberculosis infection if the amount of IL12Rβ1 isoform 2 mRNA is greater than the amount of IL12Rβ1 isoform 1 mRNA,
- d) initiating a therapeutic treatment on said patient with an active M. tuberculosis infection.
A method of monitoring a M. tuberculosis infection, comprising:
- a) providing a patient infected with M. tuberculosis,
- b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell,
- c) diagnosing the patient as having an active M. tuberculosis infection if the amount of IL12Rβ1 isoform 2 mRNA is greater than the amount of IL12Rβ1 isoform 1 mRNA,
- d) diagnosing the patient as having a latent M. tuberculosis infection if the amount of IL12Rβ1 isoform 1 mRNA is greater than the amount of IL12Rβ1 isoform 2 mRNA,
- c) initiating a therapeutic treatment if the patient has an active M. tuberculosis infection.
(canceled)
A method of monitoring a patient's response to treatment for an active M. tuberculosis infection, comprising:
- a) providing a patient with an active M. tuberculosis infection,
- b) initiating a therapeutic treatment on said patient,
- b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell, and
- c) continuing said therapeutic treatment if the ratio of IL12Rβ1 isoform 1 mRNA to IL12Rβ1 isoform 2 mRNA increases.
(canceled)
A method of monitoring a patient's response to treatment for an active M. tuberculosis infection, comprising:
- a) providing a patient with an active M. tuberculosis infection,
- b) initiating a therapeutic treatment on said patient,
- b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient during the course of said treatment, wherein said cell is a peripheral blood mononuclear, and
- c) diagnosing said patient as responding to said treatment when the ratio of IL12Rβ1 isoform 2 mRNA to IL12Rβ1 isoform 1 mRNA decreases.
(canceled)
Dependencies are inferred from the claim text.